View Item 

Show simple item record

p21: a monitor of p53 dysfunction in ovarian neoplasia

dc.contributor.authorShigemasa, K.en_US
dc.contributor.authorHu, C.en_US
dc.contributor.authorWest, C. M.en_US
dc.contributor.authorMoon, S. H.en_US
dc.contributor.authorParham, G. P.en_US
dc.contributor.authorParmley, T. H.en_US
dc.contributor.authorKorourian, S.en_US
dc.contributor.authorBaker, V. V.en_US
dc.contributor.authorO'Brien, T. J.en_US
dc.date.accessioned2010-06-01T22:18:55Z
dc.date.available2010-06-01T22:18:55Z
dc.date.issued1997-07en_US
dc.identifier.citationSHIGEMASA, K . ; HU, C . ; WEST, C. M . ; MOON, S. H . ; PARHAM, G. P . ; PARMLEY, T. H . ; KOROURIAN, S . ; BAKER, V. V . ; O'BRIEN, T. J . (1997). "p21: a monitor of p53 dysfunction in ovarian neoplasia." International Journal of Gynecological Cancer 7(4): 296-303. <http://hdl.handle.net/2027.42/75326>en_US
dc.identifier.issn1048-891Xen_US
dc.identifier.issn1525-1438en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75326
dc.format.extent190756 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rightsBlackwell Science Ltd, 1997en_US
dc.subject.otherMRNA Expressionen_US
dc.subject.otherMutation Statusen_US
dc.subject.otherOvarian Canceren_US
dc.subject.otherP21en_US
dc.subject.otherP53en_US
dc.titlep21: a monitor of p53 dysfunction in ovarian neoplasiaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelObstetrics and Gynecologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gynecology Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherDepartment of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA,en_US
dc.contributor.affiliationotherDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA,en_US
dc.contributor.affiliationotherDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA,en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75326/1/j.1525-1438.1997.00457.x.pdf
dc.identifier.doi10.1046/j.1525-1438.1997.00457.xen_US
dc.identifier.sourceInternational Journal of Gynecological Canceren_US
dc.identifier.citedreferenceBoring CC, Squires TS, Tong T. Cancer Statistics 1992; 7: 19 – 38.en_US
dc.identifier.citedreferenceAverette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma. Cancer 1993; 7: 1629 – 38.en_US
dc.identifier.citedreferenceHunter T. Cooperation between oncogenes. Cell 1991; 7: 249 – 70.en_US
dc.identifier.citedreferenceBast RC, Boyer CM, Jacobs I. et al. Cell growth retardation in epithelial ovarian cancer. Cancer 1993; 7: 1597 – 601.en_US
dc.identifier.citedreferenceKastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craid RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 7: 6304 – 11.en_US
dc.identifier.citedreferenceShah P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 7: 4495 – 9.en_US
dc.identifier.citedreferenceLowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 7: 847 – 9.en_US
dc.identifier.citedreferenceXiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 7: 701 – 4.en_US
dc.identifier.citedreferenceEl-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 7: 817 – 25.en_US
dc.identifier.citedreferenceHarper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 7: 805 – 16.en_US
dc.identifier.citedreferenceNoda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 7: 90 – 8.en_US
dc.identifier.citedreferenceShinohara M, El-Deiry WS, Wada M, et al. Absence of WAF1 mutation in a variety of human malignancies. Blood 1994; 7: 3781 – 4.en_US
dc.identifier.citedreferenceNoonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multi-drug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 7: 7160 – 4.en_US
dc.identifier.citedreferenceLamb P & Crawford L. Characterization of the human p53 gene. Mol Cell biol 1986; 7: 1379 – 85.en_US
dc.identifier.citedreferenceHall JL, Dudley L, Dobner PR, Lewis SA, Cowan NJ. Identification of two human β-tubulin isotopes. Mol Cell Biol 1983; 7: 854 – 62.en_US
dc.identifier.citedreferenceWeinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 7: 323 – 30.en_US
dc.identifier.citedreferenceNigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 7: 705 – 8.en_US
dc.identifier.citedreferenceKupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutation and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 7: 4961 – 5.en_US
dc.identifier.citedreferenceMilner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 7: 2128 – 32.en_US
dc.identifier.citedreferenceKohler MF, Marks JR, Wiseman RW, et al.. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 7: 1513 – 19.en_US
dc.identifier.citedreferenceNiwa K, Itoh M, Murase T, et al. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 1994; 7: 1191 – 7.en_US
dc.identifier.citedreferenceMcManus DT, Yap EPH, Maxwell P, Russel SEH, Toner PG, McGee J’OD. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 1994; 7: 159 – 68.en_US
dc.identifier.citedreferenceTeneriello MG, Ebina M, Linnoila RI, et al. p53 and K-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993; 7: 3103 – 8.en_US
dc.identifier.citedreferenceLevine AJ, Perry ME, Chang A, et al. The role of the p53 tumor-suppressor gene in tumorigenesis. Br J Cancer 1994; 7: 409 – 16.en_US
dc.identifier.citedreferenceRogel A, Popliker M, Webb CG, Oren M, Webb CG, Oren M. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos and tumors. Mol Cell Biol 1985; 7: 2851 – 5.en_US
dc.identifier.citedreferenceFinlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 7: 531 – 9.en_US
dc.identifier.citedreferenceWerness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 7: 76 – 9.en_US
dc.identifier.citedreferenceChen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 7: 107 – 14.en_US
dc.identifier.citedreferenceOliner JD, Pietenpol JA, Thiagalingam S, Gyures J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993; 7: 857 – 60.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1525-1438.1997.00457.x.pdf
Size:
186.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.